• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Bangalore, March 14

Strides Arcolab has said it has received tentative USFDA approvals for two more anti-HIV NDAs (new drug applications). This takes the total NDAs/ANDAs (abbreviated NDA) approvals received to eight.

The latest approvals are for fixed dose combination of lamivudine/ stavudine 150 mg/40 mg tablets; and lamivudine / stavudine 150/40 mg tablets co-packaged with Nevirapine 200 mg tablets, an official release said. Both were approved under the expedited review provisions of the PEPFAR (President's Emergency Plan for Aids Relief) programme. Mr Arun Kumar, Vice-Chairman and MD of Strides Arcolab, said the two new approvals were key products in the treatment of HIV and would provide a boost to Strides' TB and malaria initiative.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Biocon arm to set up research facility for Bristol Myers

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line